These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 6877194)

  • 1. [Patient compliance in iron-chelating therapy of beta-thalassemia major].
    Di Gregorio F; Romeo MA; Tasca R; Passaniti G
    Minerva Pediatr; 1983 May; 35(10):489-93. PubMed ID: 6877194
    [No Abstract]   [Full Text] [Related]  

  • 2. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Electrocardiographic and radiologic evaluation in cardiac involvement in patients with beta-thalassemia major].
    Lo Jacono F; Agnello D; Malizia R; Maltese I; Marasa' R
    Pediatria (Napoli); 1980 Sep; 88(3):385-93. PubMed ID: 7220158
    [No Abstract]   [Full Text] [Related]  

  • 6. Intensive transfusion therapy in thalassemia major.
    Beard ME; Necheles TF; Allen DM
    Pediatrics; 1967 Nov; 40(5):911-5. PubMed ID: 6075668
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
    Chan GC; Ng DM; Fong DY; Ha SY; Lau YL
    Am J Hematol; 2004 Aug; 76(4):398-404. PubMed ID: 15282678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Beta-thalassemia major in children and adolescents in Denmark].
    Jung A; Main KM; Scheibel E; Peitersen B; Clausen N; Erichsen G; Schmiegelow K; Illum N
    Ugeskr Laeger; 2002 Dec; 164(49):5803-6. PubMed ID: 12523224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hereditary anemia: genetic basis, clinical characteristics, diagnosis and treatment. WHO Workgroup].
    Bull World Health Organ; 1983; 61(2):179-98. PubMed ID: 6345012
    [No Abstract]   [Full Text] [Related]  

  • 14. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Respiratory function tests in adolescents with beta-thalassemia major (author's transl)].
    Secchi GC; Scotti PG; Cambiaghi G; Aresini G; De Carli A; Guerrieri MC
    Haematologica; 1982 Feb; 67(1):23-32. PubMed ID: 6800901
    [No Abstract]   [Full Text] [Related]  

  • 17. Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia.
    Origa R; Tatti F; Zappu A; Leoni GB; Dessì C; Moi P; Morittu M; Orecchia V; Denotti AR; Pilia MP; Anni F; Perra M; Casini MR; Barella S
    Am J Hematol; 2017 Nov; 92(11):E627-E628. PubMed ID: 28741691
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term effects of combined therapy in patients with beta-thalassemia major].
    Bagnulo S; Giannini AM; Moscatelli F; Stragapede L; Acquafredda A; Dammacco A
    Pediatr Med Chir; 1998; 20(1):33-7. PubMed ID: 9658419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early iron chelation therapy in thalassemia major.
    Russo G; Romeo MA; Musumeci S; Schilirò G; Di Gregorio F
    Haematologica; 1983; 68(1):69-73. PubMed ID: 6404710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.